The short answer: choose a laboratory where clinical research preceded the market introduction of the test, and where validation data are preferably available in a peer-reviewed medical journal or reputable medical platform. But let us look more closely at why this matters.

Twenty years ago, reliable laboratories specializing in chronic infection diagnostics were scarce. Today, however, we are almost overwhelmed by the number of available options. When selecting a laboratory test, it is essential to consider several key factors and to understand which cost components laboratories incorporate into their pricing — and why one lab may be significantly less expensive while another charges considerably more.

Acute vs. Chronic Infections: A Fundamental Difference

An important starting point is that mainstream medicine recognizes relatively few chronic infectious diseases (for example, HIV or tuberculosis). Most well-characterized infectious diseases — particularly bacterial ones — present in an acute form. Accordingly, the majority of insurance-funded and commercially available tests have been calibrated to detect pathogens responsible for acute illnesses.

In acute cases, calibration is relatively straightforward. Symptoms are typically pronounced, pathogen load and replication rates are high, and the immune system responds vigorously with elevated antibody levels.

The main objective of calibration is to establish appropriate cut-off values — in other words, determining the threshold above which a result is considered positive. These thresholds must be set in a way that allows the highest possible certainty in confirming the presence of infection.

If the threshold is set too low, false-positive results may occur. After all, some level of antibodies is often present from past infections, and cross-reactivity between pathogens can also lead to misleading results.

If the threshold is set too high, the opposite problem arises: a truly infected individual may receive a false-negative result.

Because acute diseases are well studied, these cut-off values have been established over decades. Many commercial laboratories simply purchase complete test kits, where the manufacturer already provides validated threshold values.

Why Chronic Infection Testing Is More Complex

In chronic infections, the situation is far more complicated. Each laboratory method typically requires its own dedicated research and calibration process before being introduced to the market. There are no universally established cut-off values, and ready-made test kits are often unavailable.

Looking specifically at antibody responses, additional challenges arise:

• Elevated IgM responses are generally not characteristic of chronic infection.

• Increased IgG levels are difficult to distinguish from immunity resulting from a past, resolved infection.

• Some pathogens possess immune-modulating capabilities, meaning that active chronic infection may be associated with only low antibody levels — sometimes below the detection limit of conventional methods.

Therefore, a single formula or single methodology cannot reliably cover all bacterial pathogens.

Such research is extremely capital-intensive. Currently, these developments are primarily conducted by private laboratories, with American labs playing a dominant role in this segment of the market.

The Cost of Proper Validation

Before a test can be introduced to the market, statistically significant calibration must be performed. This involves comparing a substantial number of confirmed positive samples (patients with clinically and independently verified infection) with an equivalent number of negative controls (healthy, asymptomatic individuals).

The goal is to determine a positivity threshold that:

• Identifies as many truly infected individuals as possible (sensitivity),

• While avoiding positive results in healthy individuals (specificity).

Even a study design involving 100 positive and 100 negative control samples represents a significant logistical and financial undertaking. Nevertheless, such validation is essential for ensuring reliable diagnostic performance.

These studies should ideally be published in recognized and respected medical journals. Publication supports a laboratory’s credibility, as submitted manuscripts undergo independent peer review before acceptance.

Naturally, the substantial costs associated with pre-market research and validation are incorporated into the final price of the test. This explains why some chronic infection panels may cost significantly more than routine tests designed for acute infections.

Key Considerations When Choosing a Laboratory

In summary, when selecting a laboratory and diagnostic test, one of the most important criteria is how much the laboratory has invested in proper calibration and validation.

Ask the following questions:

• Was clinical research conducted before market release?

• Is there a published and accessible study?

• Are sensitivity and specificity clearly stated?

• Is the methodology transparent?

Finally, because each laboratory operates with specific technologies and equipment, one lab may be particularly well suited for a certain type of test for a given bacterium, while another lab may excel in a different detection method for the same pathogen.

Choosing the right laboratory, therefore, is not only about price — it is about scientific rigor, validation quality, and methodological expertise.